Paradoxical activation of oncogenic signaling as a cancer treatment strategy
M. H. Dias, A. Friskes, S. Wang, J. M. H. Fernandes Neto, F. v. Gemert, S. Mourragui, H. J. Kuiken, S. Mainardi, D. Alvarez-Villanueva, C. Lieftink, B. Morris, A. Dekker, E. v. Dijk, C. Papagianni, M. S. da Silva, R. Jansen, A. Mulero-Sanchez, E. Malzer, A. Vidal, C. Santos, R. Salazar, R. A. M. Wailemann, T. E. P. Torres, G. De Conti, J. Raaijmakers, , R. Bernards
Abstract
Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress-response programs that counteract the inherent toxicity of such aberrant signaling. While inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of Protein Phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor suppressive resistance.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PEBP1 is a candidate biomarker of response to the PP2A inhibitor LB-100
Matheus Henrique Dias, Chrysa Papagianni, René Bernards·bioRxiv·Feb 25, 2025
- Dual Drug Targeting to Kill Colon Cancer Cells
A. W. Burgess, M. C. Faux, … F. Walker·bioRxiv·Feb 28, 2021
- PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma
Garima Baral, Claire M. Pfeffer, … Brittany L. Allen-Petersen·bioRxiv·Jul 14, 2025
- PP2A inhibition instructs spliceosome phosphorylation to create splicing vulnerability in colon adenocarcinoma
M. H. Dias, V. Liudkovska, … M. Ciesla·bioRxiv·Jul 12, 2023
- PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer
Sahar F. Bannoura, Husain Yar Khan, … Asfar S. Azmi·bioRxiv·Dec 10, 2025
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death
R. Avelar, A. Armstrong, … A. DiFeo·bioRxiv·Jun 10, 2022